NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Prokarium

Prokarium

Private
LondonHealthcare & Life Scienceshttps://www.prokarium.com/

Last Round

Corporate Funding

Dec 2, 2025

Total Funding Raised

$73.87M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Prokarium is a biotechnology company that develops microbial immunotherapies for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

microbial immunotherapyengineered Salmonellalive biotherapeuticsolid tumorsbladder cancersynthetic biology platformNMIBCcancer immunotherapyBCG unresponsivebacteriotherapyintravesical therapyclinical-stage biotechLiving Curesnon-muscle invasive bladder cancerRNA deliveryBactofection

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Prokarium Comparables

Compare Prokarium with similar companies based on industry and business-model similarity.

Prokarium comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Actym Therapeutics
83%
Vaxiion Therapeutics
82%
Shaoxing Salvectors Biotechnology Ltd.
81%

Prokarium Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingDec 2, 2025
GrantMar 14, 2024
Series CFeb 9, 2023
Series BOct 27, 2020
GrantOct 8, 2019
Series A
Feb 26, 2018

Key People

Founding team and executive leadership

Kristen Albright

Chief Executive Officer

Executive Team

Prokarium Investors

Notable investors and investment history

Prokarium investors
InvestorRounds
Korea Investment PartnersSeries A
Flerie InvestSeries B, Series A, Series C
Innovate UKGrant
SynbiCITEGrant, Series C
Korea Investment HoldingsSeries C
Biotechnology and Biological Sciences Research CouncilGrant
Korea Investment PartnersSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Will present interim clinical data at the 2026 AUA Annual Meeting.

  • Mar 13, 2026

    Will present interim clinical data at the EAU Annual Congress in London.

Prokarium Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Prokarium Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Prokarium's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range17
Year Founded2012
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.